Greywolf Therapeutics
Phase 1/2Novel antigen modulation technology that controls T cells to guide the immune system
Founded
2018
Focus
Small Molecules
About
Novel antigen modulation technology that controls T cells to guide the immune system
Funding History
1Total raised: $3.8M
Seed$3.8MUndisclosedAug 15, 2021
Company Info
TypePrivate
Founded2018
LocationOxford, United Kingdom
StagePhase 1/2
Contact
SIMILAR COMPANIES
Abbexa
Pre-clinical · Cambridge
Accentus Medical
Pre-clinical · Oxford
AbOliGo
Pre-clinical · London
Bigespas
Pre-clinical · London
Actimed Therapeutics
Pre-clinical · London
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile